IP Library Granted Patent US 7,976,833
Granted Patent B2
US 7,976,833 · App. 11/548,076 · Granted Jul 12, 2011

Ophthalmic surgical irrigating solutions containing hyaluronidase and method for preventing post-operative intraocular pressure increases

Assignee: Aspen Biomedical Research, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,976,833
App. No.
11/548,076
Granted
Jul 12, 2011
Kind
B2
Abstract

An ophthalmic irrigating solution containing hyaluronidase and an antioxidant is provided. The solution prevents a post-operative intraocular pressure rise when used during an ophthalmic surgical procedure, and also protects corneal endothelial cells. A method for preventing post-operative intraocular pressure increases in an eye during ophthalmic surgery involves irrigating an anterior chamber of the eye with an ophthalmic solution containing hyaluronidase and an antioxidant. Kits containing hyaluronidase and base medium solutions are also provided. The kits are designed such that the hyaluronidase and base medium solution are combined and administered together to an eye of a patient during or following an ophthalmic surgical procedure, such as cataract surgery, intraocular lens surgery, corneal transplant surgery, or glaucoma surgery. Administration of the components of the kit prevents an increase in post-operative intraocular pressure and also protects corneal endothelial cells.

Claims (10)

1. A method for preventing a post-operative intraocular pressure increase in an eye, the method comprising performing an ophthalmic surgical procedure on an eye and irrigating an anterior chamber of the eye with an ophthalmic solution comprising hyaluronidase, β-hydroxybutyrate, and an antioxidant during the procedure such that a post-operative intraocular pressure in the eye is at a substantially pre-operative level.

2. The method according to claim 1 , wherein the pre-operative level of intraocular pressure is less than about 20 mm Hg gauge.

3. The method according to claim 1 , wherein the surgical procedure is selected from the group consisting of cataract surgery, intraocular lens surgery, corneal transplant surgery, and glaucoma surgery.

4. The method according to claim 1 , wherein the solution comprises about 0.1 to about 25 units hyaluronidase per ml of the solution.

5. The method according to claim 1 , further comprising continuously irrigating and aspirating the solution into and from the eye during the surgical procedure.

6. The method according to claim 1 , wherein the method prevents endothelial cell damage in the eye during the surgical procedure.

7. The method according to claim 1 , further comprising injecting the solution into an anterior chamber of the eye during or following the surgical procedure.

8. The method according to claim 1 , further comprising topically applying the solution to a surface of the eye during or following the surgical procedure.

9. The method according to claim 1 , further comprising preparing the irrigating solution by combining hyaluronidase, β-hydroxybutyrate, and an antioxidant with a solution comprising a base medium.

10. The method according to claim 9 , wherein the solution further comprises at least one component selected from the group consisting of an energy source, ATP and precursors thereof, and a component for maintaining cell density and/or cell viability.

Assignments (2)
MERGER Recorded Jun 23, 2011
From: ASPEN BIOMEDICAL RESEARCH, LLC.
To: CLEO COSMETIC AND PHARMACEUTICAL CO., LLC.
Reel/Frame 026491/0164 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2007
From: SOLL, DAVID B.
To: ASPEN BIOMEDICAL RESEARCH, LLC
Reel/Frame 018794/0982 →
Continuity (2)
Provisional Application 60726571 · Oct 14, 2005
Related Publication 20070137657A1 · Jun 21, 2007